Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Work In Process for 3 consecutive years, with $12.1 million as the latest value for Q1 2025.

  • On a quarterly basis, Work In Process rose 104.4% to $12.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $12.1 million, a 104.4% increase, with the full-year FY2024 number at $8.8 million, up 52.46% from a year prior.
  • Work In Process was $12.1 million for Q1 2025 at Iovance Biotherapeutics, up from $8.8 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $12.1 million in Q1 2025 to a low of $4.3 million in Q3 2023.
  • A 3-year average of $7.6 million and a median of $7.3 million in 2023 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: surged 52.46% in 2024, then skyrocketed 104.4% in 2025.
  • Iovance Biotherapeutics' Work In Process stood at $5.7 million in 2023, then soared by 52.46% to $8.8 million in 2024, then surged by 37.91% to $12.1 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Work In Process are $12.1 million (Q1 2025), $8.8 million (Q4 2024), and $5.9 million (Q1 2024).